Addex Therapeutics Ltd (ADR) ( (ADXN) ) has released its Q4 earnings. Here is a breakdown of the information Addex Therapeutics Ltd (ADR) presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Addex Therapeutics Ltd (ADR) is a biopharmaceutical company focused on developing small molecule allosteric modulators for treating neurological disorders, with a strong emphasis on addressing diseases with high unmet medical needs in the central nervous system sector. In its 2024 annual report, Addex Therapeutics highlighted significant financial and strategic developments, including a major transaction with Neurosterix and advancements in its drug development pipeline. Key financial metrics revealed a net profit of CHF 7.1 million for 2024, a significant turnaround from a net loss of CHF 10.6 million in 2023, primarily due to a CHF 13.9 million gain from the sale of part of its business to Neurosterix. The company also reported a decrease in revenue from continuing operations to CHF 0.4 million, reflecting the completion of certain research phases. Looking ahead, Addex Therapeutics plans to focus on securing strategic partnerships and investments to advance its portfolio of drug candidates, aiming to strengthen its position in the biopharmaceutical industry.